Press Releases

Press Releases

Filters
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
Viatris Named Fifth on Fortune's Change the World List
Viatris Inc. to Participate in Citi's 16th Annual BioPharma Conference
Viatris Inc. to Participate in BofA Global Healthcare Conference
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
Displaying 71 - 80 of 98